Last Price$29.3(3.2%)
Market Cap$1,656.1M
$10.6M
+31.0% YoY
($69.0M)
+18.4% YoY
($1,002.1M)
Net Debt to FCF - 22.7x
($44.2M)
(417.2% margin)
JANX Income Statement
JANX Income Statement Overview
Annual
Quarterly
LTM
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
JANX Income statement key metrics
Annual
Quarterly
LTM
JANX Balance Sheet
JANX Balance Sheet Overview
Annual
Quarterly
LTM
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
Assets
Liabilities
Total assets
$1,061.5M
Current assets ($1,033.7M, 97.4% of total)
$1,025.2M (96.6%)
$0.0 (0.0%)
Other current assets
$8,493.0K (0.8%)
Non-current assets ($27.9M, 2.6% of total)
$0.0 (0.0%)
$24.2M (2.3%)
$0.0 (0.0%)
Other non-current assets
$3,700.0K (0.3%)
Financial position
($1,002.1M)
Cash & Short-term
Investments
Total Debt
JANX Balance Sheet Metrics
Annual
Quarterly
LTM
JANX Cash Flow Statement
JANX Cash Flow Statement Overview
Annual
Quarterly
LTM
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
$411.4M Net Change in Cash
JANX Cash Flow Statement key metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
($43.8M) -13.4% YoY
Capital Expenditure (CAPEX)
($359.0K) -80.6% YoY
Free Cash Flow (FCF)
($44.2M) -15.7% YoY
JANX Financials
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 3.6 0.0% | 8.6 136.8% | 8.1 (6.1%) | 10.6 31.0% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.1 | 0.8 | 2.0 | 0.0 |
% margin | (0.0) 0.0% | (0.0) 0.0% | 3.5 96.9% | 7.8 90.2% | 6.1 75.8% | 10.6 100.0% |
| Operating Expenses | 3.8 | 4.8 | 36.6 | 75.7 | 81.1 | 109.4 |
| Research & Development Expenses (R&D) | 3.0 | 3.0 | 26.2 | 53.4 | 54.9 | 68.4 |
| Selling, General & Administrative Expenses (SG&A) | 0.8 | 1.8 | 10.3 | 22.3 | 26.1 | 41.0 |
% margin | (3.8) 0.0% | (4.8) 0.0% | (32.9) (905.4%) | (67.1) (779.0%) | (73.0) (902.9%) | (98.8) (933.6%) |
| Interest Income | 0.2 | 0.2 | 0.3 | 4.0 | 14.7 | 29.9 |
| Interest Expense | 0.2 | 0.2 | 0.0 | 4.0 | 0.0 | 0.0 |
| Pre-tax Income | (4.0) | (6.8) | (32.7) | (63.1) | (58.3) | (69.0) |
% effective tax rate | 0.2 (5.8%) | (1.5) 22.5% | (0.1) 0.3% | (8.9) 14.1% | 0.0 0.0% | 0.0 0.0% |
% margin | (4.2) 0.0% | (5.3) 0.0% | (32.6) (895.2%) | (54.2) (628.8%) | (58.3) (721.2%) | (69.0) (651.6%) |
| EPS | (0.10) | (0.13) | (0.79) | (1.31) | (1.32) | (1.28) |
| Diluted EPS | (0.10) | (0.13) | (0.79) | (1.31) | (1.32) | (1.28) |
% margin | (3.8) 0.0% | (4.8) 0.0% | (32.8) (902.3%) | (66.3) (769.3%) | (71.0) (878.7%) | (98.8) (933.6%) |
FAQ
What is the Janux Therapeutics, Inc. (JANX) revenue?
The Janux Therapeutics, Inc. (JANX) revenue is $10.6M, reflecting a year-over-year (YoY) growth of +31.0% YoY.
What is the Janux Therapeutics, Inc. (JANX) Net Income?
The Janux Therapeutics, Inc. (JANX) Net Income is ($69.0M), showcasing a YoY growth of +18.4% YoY.
What is Janux Therapeutics, Inc. (JANX) net debt?
What is the Janux Therapeutics, Inc. (JANX) Free Cash Flow (FCF)?
The Janux Therapeutics, Inc. (JANX) Free Cash Flow (FCF) stands at ($44.2M), accounting for a (417.2%) margin.